157 related articles for article (PubMed ID: 38661301)
1. Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review.
Bytyci J; Ying Y; Lee LYW
Immun Inflamm Dis; 2024 Apr; 12(4):e1259. PubMed ID: 38661301
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
Embi PJ; Levy ME; Naleway AL; Patel P; Gaglani M; Natarajan K; Dascomb K; Ong TC; Klein NP; Liao IC; Grannis SJ; Han J; Stenehjem E; Dunne MM; Lewis N; Irving SA; Rao S; McEvoy C; Bozio CH; Murthy K; Dixon BE; Grisel N; Yang DH; Goddard K; Kharbanda AB; Reynolds S; Raiyani C; Fadel WF; Arndorfer J; Rowley EA; Fireman B; Ferdinands J; Valvi NR; Ball SW; Zerbo O; Griggs EP; Mitchell PK; Porter RM; Kiduko SA; Blanton L; Zhuang Y; Steffens A; Reese SE; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron MA; Thompson MG; DeSilva MB
MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1553-1559. PubMed ID: 34735426
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.
Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N
Front Immunol; 2023; 14():1204831. PubMed ID: 37771594
[TBL] [Abstract][Full Text] [Related]
4. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.
Galmiche S; Luong Nguyen LB; Tartour E; de Lamballerie X; Wittkop L; Loubet P; Launay O
Clin Microbiol Infect; 2022 Feb; 28(2):163-177. PubMed ID: 35020589
[TBL] [Abstract][Full Text] [Related]
5. COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.
Lee LYW; Ionescu MC; Starkey T; Little M; Tilby M; Tripathy AR; Mckenzie HS; Al-Hajji Y; Appanna N; Barnard M; Benny L; Burnett A; Cattell EL; Clark JJ; Khan S; Ghafoor Q; Panneerselvam H; Illsley G; Harper-Wynne C; Hattersley RJ; Lee AJ; Lomas O; Liu JK; McCauley A; Pang M; Pascoe JS; Platt JR; Patel G; Patel V; Potter VA; Randle A; Rigg AS; Robinson TM; Roques TW; Roux RL; Rozmanowski S; Taylor H; Tuthill MH; Watts I; Williams S; Beggs A; Iveson T; Lee SM; Middleton G; Middleton M; Protheroe A; Fittall MW; Fowler T; Johnson P;
Eur J Cancer; 2022 Nov; 175():1-10. PubMed ID: 36084618
[TBL] [Abstract][Full Text] [Related]
6. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Pessina G; Natoni F; Silvestri MA; Ruggeri EM
Curr Oncol; 2023 May; 30(5):5103-5115. PubMed ID: 37232844
[TBL] [Abstract][Full Text] [Related]
7. Vaccination and COVID-19 Dynamics in Dialysis Patients.
El Karoui K; Hourmant M; Ayav C; Glowacki F; Couchoud C; Lapidus N;
Clin J Am Soc Nephrol; 2022 Mar; 17(3):395-402. PubMed ID: 35144970
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews.
Tan TT; Ng HJ; Young B; Khan BA; Shetty V; Azmi N; Clissold S
Expert Rev Vaccines; 2023; 22(1):341-365. PubMed ID: 36920116
[TBL] [Abstract][Full Text] [Related]
9. Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients.
Han A; Min S; Jo EA; Lee H; Kim YC; Han SS; Kang HG; Ahn YH; Oh I; Song EY; Ha J
Ann Lab Med; 2024 Jan; 44(1):64-73. PubMed ID: 37665287
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Imaging Characteristics of SARS-CoV-2 Breakthrough Infection in Hospitalized Immunocompromised Patients.
Lee JE; Kim J; Hwang M; Kim YH; Chung MJ; Jeong WG; Jeong YJ
Korean J Radiol; 2024 May; 25(5):481-492. PubMed ID: 38627873
[TBL] [Abstract][Full Text] [Related]
11. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
Smits PD; Gratzl S; Simonov M; Nachimuthu SK; Goodwin Cartwright BM; Wang MD; Baker C; Rodriguez P; Bogiages M; Althouse BM; Stucky NL
Vaccine; 2023 Apr; 41(15):2447-2455. PubMed ID: 36803895
[TBL] [Abstract][Full Text] [Related]
12. Association of COVID-19 Vaccination With Risk of COVID-19 Infection, Hospitalization, and Death in Heart Transplant Recipients.
Peters LL; Raymer DS; Pal JD; Ambardekar AV
JAMA Cardiol; 2022 Jun; 7(6):651-654. PubMed ID: 35475896
[TBL] [Abstract][Full Text] [Related]
13. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.
Kshirsagar M; Nasir M; Mukherjee S; Becker N; Dodhia R; Weeks WB; Ferres JL; Richardson B
JMIR Public Health Surveill; 2022 Nov; 8(11):e38898. PubMed ID: 36265135
[TBL] [Abstract][Full Text] [Related]
14. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
Malek AE; Cornejo PP; Daoud N; Alam M
Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
[No Abstract] [Full Text] [Related]
15. SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis.
Manley HJ; Li NC; Aweh GN; Hsu CM; Weiner DE; Miskulin D; Harford AM; Johnson D; Lacson E
Am J Kidney Dis; 2023 Apr; 81(4):406-415. PubMed ID: 36462570
[TBL] [Abstract][Full Text] [Related]
16. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.
Lee LYW; Starkey T; Ionescu MC; Little M; Tilby M; Tripathy AR; Mckenzie HS; Al-Hajji Y; Barnard M; Benny L; Burnett A; Cattell EL; Charman J; Clark JJ; Khan S; Ghafoor Q; Illsley G; Harper-Wynne C; Hattersley RJ; Lee AJX; Leonard PC; Liu JKH; ; Pang M; Pascoe JS; Platt JR; Potter VA; Randle A; Rigg AS; Robinson TM; Roques TW; Roux RL; Rozmanowski S; Tuthill MH; Watts I; Williams S; Iveson T; Lee SM; Middleton G; Middleton M; Protheroe A; Fittall MW; Fowler T; Johnson P
Lancet Oncol; 2022 Jun; 23(6):748-757. PubMed ID: 35617989
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2.
Di Fusco M; Moran MM; Cane A; Curcio D; Khan F; Malhotra D; Surinach A; Miles A; Swerdlow D; McLaughlin JM; Nguyen JL
J Med Econ; 2021; 24(1):1248-1260. PubMed ID: 34844493
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients.
Vanlerberghe B; Vrij C; Bogaerts K; Vermeersch P; Lagrou K; Molenberghs G; Rega F; Ceulemans LJ; van Raemdonck D; Jochmans I; Monbaliu D; Pirenne J; Vanuytsel T; Gillard P; Schoemans H; Cleemput JV; Kuypers D; Vos R; Nevens F; Verbeek J
J Med Virol; 2023 Apr; 95(4):e28736. PubMed ID: 37185854
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 breakthrough infections in rheumatic diseases patients after vaccination.
Alshukairi AN; Al-Omari A; Albeity A; Alandijany TA; Hassan AM; El-Kafrawy SA; Dada A; Al Hroub MK; El-Saed A; Bissar LS; Daghmush RM; Al-Ghamdi SMG; Perlman S; Azhar EI; Halabi H
J Infect Public Health; 2022 Jun; 15(6):685-688. PubMed ID: 35623243
[TBL] [Abstract][Full Text] [Related]
20. Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer.
Gong IY; Vijenthira A; Powis M; Calzavara A; Patrikar A; Sutradhar R; Hicks LK; Wilton D; Singh S; Krzyzanowska MK; Cheung MC
JAMA Oncol; 2023 Mar; 9(3):386-394. PubMed ID: 36580318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
